Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Verisante Technology Inc. V.VRS


Primary Symbol: V.VER.H

Verisante Technology Inc is a Canada based medical device company. It is engaged in commercializing medical systems for the early detection of cancer. The products of the company are Verisante Aura which is for skin cancer detection and Verisante Core which is for lung, colon and cervical cancer detection. It utilizes a cancer detection platform while the operating software and probe technology. The group generates revenue from the sale and renting of its medical devices.


TSXV:VER.H - Post by User

Bullboard Posts
Post by AnalyticalTraderon Jan 03, 2012 1:42pm
416 Views
Post# 19366189

Things to be aware of

Things to be aware of

1. The bid prices are set to prey at and profit from shareholders with unrealistic expectations on the stock. 

2. Traders set up the back and fro between 0.66 and 0.70 to play with the minds of newcomers. 

3. Text-book technical analysis suggests that when support is established and visible, it's a right time to buy. 

4. The growth of the sp will be steady and possibly bumpy. Horizon for the endearing 2.60$ target is best set against the first news of contract or order or earning projection. 

5. A new round of media coverage is expected, as the company pursues FDA approval.  

Bullboard Posts